Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| COVID-19 Trials and Actions | |||
| Altimmune | AdCOVID | single-dose intranasal COVID-19 vaccine | IND approved by the FDA |
| AIM ImmunoTech | Ampligen intranasal therapy | prophylaxis or treatment for COVID-19 and other respiratory viral diseases | approval from the Ethics Committee in the Netherlands to begin phase 1 trial |
| Adagio Therapeutics | ADG20 | treatment and prevention of COVID-19 | initiation of phase 1 trial |
| ImmunityBio NantKwest |
bivalent hAd5 T-cell COVID-19 vaccine | COVID-19 vaccine | approval to expand phase 1 trial to include subcutaneous, oral and sublingual boost |
| ReAlta Life Sciences | RLS-0071 | acute lung injury as a result of viral infection, including COVID-19, RSV and influenza | first patient dosed in phase 1 trial |
| Diffusion Pharmaceuticals | trans sodium crocetinate | hospitalized COVID-19 patients with confirmed hypoxemia | completion of phase 1b trial |
| Clene Nanomedicine | CNM-ZnAg liquid solution | acutely symptomatic, nonhospitalized COVID-19 patients | initiation of phase 2 trial |
| RedHill Biopharma | RHB-107 (upamostat) | patients with symptomatic COVID-19 who do not require hospital care | first patient dosed in phase 2/3 trial |
| AstraZeneca-Oxford | COVID-19 vaccine | COVID-19 | Emergency Use Authorization (EUA) granted by the World Health Organization |
| Becton, Dickinson and Company | BD SARS-CoV-2/Flu assay | molecular diagnostic test for both SARS-CoV-2 and influenza A+B | EUA granted by the FDA |
| Everlywell | Everlywell COVID-19 Test Home Collection Kit | detection of COVID-19 in asymptomatic individuals who have no suspected exposure to COVID-19 | EUA granted by the FDA for direct-to-consumer distribution |
| GenScript | cPass SARS-CoV-2 Neutralization Antibody Detection Kit | detection of COVID-19 neutralizing antibodies without the use of live virus | EUA granted by the FDA |
| Luminostics | Clip COVID Rapid Antigen Test | detection of COVID-19 | EUA granted by the FDA |
| Other Trials and Actions | |||
| Akan Biosciences | StroMel | osteoarthritis of the knee | IND approved by the FDA |
| Lysogene | LYS-GM101 | GM1 gangliosidosis | IND approved by the FDA |
| Signature Biologics | Signature Cord Prime | osteoarthritis of the knee | IND approved by the FDA |
| Avacta Group | AVA6000 pro-doxorubicin | FAP-positive locally advanced or metastatic solid tumors | clinical trial authorization granted by the UK Medicines and Healthcare products Regulatory Agency |
| Asklepios Bio Selecta Bio |
SEL-399 combined with ImmTOR | mitigate unwanted immune responses associated with gene therapies | initiation of phase 1 trial |
| Inhibikase Therapeutics | IkT-148009 | Parkinson’s disease | first patients dosed in phase 1 trial |
| Ultimovacs | Tetanus-Epitope Targeting (TET)-platform | relapsed prostate cancer | first patient dosed in phase 1 trial |
| vTv Therapeutics | HPP737 | psoriasis | initiation of phase 1 trial |
| Salarius Pharma | seclidemstat | relapsed/refractory Ewing sarcoma | completion of phase 1 portion of phase 1/2 trial |
| Kintara Therapeutics | VAL-083 | recurrent glioblastoma multiforme | final patient enrolled in phase 2 trial |
| NeoImmuneTech | NT-I7 (efineptakin alfa) in combinarion with Opdivo (nivolumab) | patients with previously treated advanced or metastatic gastric, gastro-esophageal junction or esophageal adenocarcinoma | first patient dosed in phase 2 trial |
| Pfizer | elranatamab (PF-06863135) | relapsed/refractory multiple myeloma | first patient dosed in phase 2 trial |
| Valbiotis | TOTUM-070 | patients with untreated mild to moderate LDL-hypercholesterolemia | approval from French regulatory authorities to initiate phase 2 trial |
| Moebius Medical | MM-II | pain due to knee osteoarthritis | first patient dosed in phase 2b trial |
| Monopar | Validive | prevention of chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer | first patient dosed in phase 2b/3 trial |
| Forge Biologics | FBX-101 | Krabbe disease | Fast-Track, Orphan Drug and Rare Pediatric Disease designations granted by the FDA |
| Oryzon | iadademstat | acute myeloid leukemia | Orphan Drug designation granted by the FDA |
| Targovax | ONCOS-102 | malignant pleural mesothelioma | Fast-Track designation granted by the FDA |
| G1 Therapeutics | Cosela (trilaciclib) | decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small-cell lung cancer | approved by the FDA |
| Novartis | Entresto (sacubitril/valsartan) | reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure | approved by the FDA for expanded indication |
| Pfizer | Panzyga (Immune Globulin Intravenous [Human] – ifas 10% Liquid Preparation) | chronic inflammatory demyelinating polyneuropathy | approved by the FDA for expanded indication |
| Regeneron | Evkeeza (evinacumab-dgnb) | adult and pediatric patients age 12 and older with homozygous familial hypercholesterolemia | approved by the FDA |
| Additive Orthopaedics | Patient Specific Talus Spacer | patient-specific total talus replacement implant | approved by the FDA |
| Delta International Service & Logistics | Scrambler Therapy Technology ST-5A | symptomatic relief of chronic opioid-resistant pain and chronic neuropathic and cancer pain | approved by the FDA |
| Shockwave Medical | Intravascular Lithotripsy | severely calcified coronary artery disease | approved by the FDA |
Upcoming Events
-
25Apr
-
26Apr
-
27Apr
-
17May
-
21May
